2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger

Leukemia

Volumn 13, Issue 4, 1999, Pages 518-523

  Robak, T ^a   Blonski J Z ^a   Urbanska Rys H ^a   Blasinska Morawiec M ^a   Skotnicki, A B ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Med Univ of Łodź ^*

Author keywords

2 chlorodeoxyadenosine; Chronic lymphocytic leukemia; Efficiency; Immunophenotyping; Side effects; Younger patients

Indexed keywords

CLADRIBINE; PURINE ANTAGONIST;

ADULT; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CHRONIC LYMPHATIC LEUKEMIA; DERMATITIS; DRUG EFFICACY; EOSINOPHILIA; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SEPSIS; THROMBOCYTOPENIA;

EID: 0344867044     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401368     Document Type: Article

References (41)

1. Catovsky D, Foa R. B-cell Chronic Lymphocytic Leukemias. Butterworths: London, 1990, pp 73-112.
2. Rozman C, Monsterrat E. Chronic lymphocytic leukemia: an update on current treatment approaches. Hematology 1997; 2: 1-9.
3. De Lima M, O'Brien S, Lerner S, Keating MJ. Chronic lymphocytic leukemia in the young patient. Semin Oncol 1998; 25: 107-116.
4. Rozman C, Bosch F, Montserrat E. Chronic lymphocytic leukemia: a changing natural history? Leukemia 1997; 11: 775-778.
5. French Cooperative Group on Chronic Lymphocytic Leukemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990; 76: 45-57.
6. Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. Br J Haematol 1989; 72: 141-149.
7. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 1987; 69: 929-936.
8. Molica S, Briugatelli M, Callea V, Morabito F, Levato D, Mobile F, Alberti A. Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. Eur J Haematol 1994; 52: 216-227.
9. Byrd JC, Rai R, Sansville EA, Grever MR. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 1998; 25: 65-74.
10. Seymour JF, Robertson LE, O'Brien S, Lerner S, Keating MJ. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for use of myeloablative therapies. Leuk Lymphoma 1995; 18: 493-496.
11. Montserrat E, Gomis F, Vallespi T. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood 1991; 78: 1545-1551.
12. Robertson LE, Hugh YO, Beutler JJ, Pugh WC, Hirsch-Ginsberg C, Stass, S, Kantarjian H, Keating MJ. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, imunophenotypic and molecular analysis. Blood 1991; 80: 29-36.
13. Robak T, Błasińska-Morawiec M, Krykowski E, Kasznicki M, Hansz J, Komarnicki M, Konopka L, Durżyński T, Ceglarek B, Sikorska A, Kotlarek-Haus S, Mazur M, Urasiński I, Zdziarska B, Maj S, Kopeć I, Skotnicki AB, Dwilewicz-Trojaczek J, Kuratowska Z, Grieb P. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1996; 22: 509-514.
14. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11: 679-689.
15. The French Cooperative Group on CLL, Johnson C, Smith AG, Loffer H, Osby E, Juliusson G, Emmerich B, Wyka PJ Hiddeman W. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukemia. Lancet 1996; 347: 1432-1438.
16. Robak T, BłasinŁska-Morawiec M, Błoński JZ, Krykowski E, Dmoszyńska A, Skotnicki AB, Konopka L, Hellmann A, Kuratowska Z, Urasiński I, Kotlarek-Haus S, Maj S. 2-Chlorodeoxyadenosine (2-CdA) and prednisone (P) versus chlorambucil (Chl) and prednisone as a first line therapy in B-cell chronic lymphocytic leukemia. Blood 1997; 90: (Suppl. 1): 530a (Abstr. 2361).
17. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempins J, Foon KA. Guidelines for chronic lymphocytic leukemia recommendations of the National Cancer Institute Sponsored Working Group. Am J Hematol 1988; 29: 152-163.
18. Rai KR, Savitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1997; 46: 219-234.
19. Kazimierczuk Z, Cottan HB, Ravauliar CR, Robins RK. Synthesis of 2′-deoxynudeosides via a novel direct stereospectific serum salt glycosylation procedure. J Am Chem Soc 1984; 106: 6379-6382.
20. Oken MM, Creech RH, Torney DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
21. Briugatelli M, Claisse JF, Lenormant B, Marabito F, Callea V, Malloum K, Chewret S, Binet JL, Digniero G, Travade P. Long term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level. Br J Haematol 1997; 97: 113-118.
22. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Janber J, Lepen G, Dreyfus B, Binett JL, Travale P. Chlorambucil in indolent chronic lymphocytic leukemia. New Engl J Med 1998; 338: 1506-1514.
23. Rai KR, Peterson B, Elias L, Sheperd L, Hines J, Nelson D. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: a CALGB, SWOG, CTG, NCI-C and ECOG Intergroup Study. Blood 1996; 88 (Suppl. 1): 141 (Abstr).
24. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44-49.
25. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
26. Keating MJ, O'Brien S, Robertson LE, Koller C, Beran M, Estey E. Chronic lymphocytic leukemia - correlation of response and survival. Leuk Lymphoma 1993; 11: 167-175.
27. Robak T, Błasińska-Morawiec M, Błoński JZ, Krykowski E, Komarnicki M, Trepińska E, Kazimierczuk M, Hansz J, Dmoszyńska A, Roliński J, Konopka L, Skotnicki AB, Nowak WS, Kotlarek-Haus S, Zdziarska B, Urasiński I. The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukemia. Eur J Cancer 1997; 33: 2347-2351.
28. Piro LD, Carrera CJ, Beutler E, Carson WA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069-1073.
29. Tallman MS, Hahimian D, Zanzig C, Hogan DK, Rademaker A, Rose E, Variakojis D. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 983-988.
30. Robak T, Błasińska-Morawiec M, Krykowski E, Hansz J, Komarnicki M, Kazimierczak M, Konopka L, Maj S, Hellmann A, Zaucha JM, Urasiński I, Zdziarska B, Kotlarek-Haus S, Usnarska-Zubkiewicz L, Kuratowska Z, Dwilewicz-Trojaczek J, Holowiecki J, Krawczyk-Kuliś M, Grieb P. 2-Chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1996; 22: 107-111.
31. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro2′-deoxyadenosine nucleotides: comparison of intermittent and intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995; 1: 385-390.
32. Liliemark J, Petterson B, Juliusson G. The relationship between plasma 2-chloro-2′-deoxyadenosine (CdA) and cellular CdA nucleotides (CdAN) after intermittent chronic lymphocytic leukemia. Blood 1991; 78 (Suppl. 1): 269a Abstr).
33. Robak T, Błasińska-Morawiec M, Krykowski E, Hellmann A, Konopka L. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol 1997; 58: 109-113.
34. Di Raimondo F, Giustolisi R, Caccida E, Kantarjian H, Robertson LB, Keating MJ. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine Leuk Lymphoma 1993; 11: 63-68.
35. Morrison VA. The infectious complications of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 98-106.
36. Betticher DC, von Rohr A, Ratschiller D, Hsu Schmitz SE, Egger T, Sonderegger T, Herrmann R, Kroner T, Zulian GB, Cavahi F, Fey MF, Cerny T. Fewer infections but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low grade non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 850-858.
37. Lerner S, Keating MJ. Fludarabine and granulocyte colony stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997; 11: 1631-1635.
38. Flinn W, Vogelsang G. Bone marrow transplantation for chronic lymphocytic leukemia. Semin Oncol 1998; 25: 60-64.
39. Lenormand B, Bizet M, Fruchant C, Tilly H, Daliphard S, Thonret F, Canipel C, Callat MP, Pignet H, Lefranc MP, Monoconduit M. Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. Leukemia 1994; 8: 1019-1026.
40. Osterborg A, Dyer MJS, Bunyes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567-1574.
41. Zinzani PL, Bendandi M, Magagnoli M, Rondelli D, de Vivo A, Benni M, Zamagni E, Cavo M, Tura S. Results of a fludarabine induction and α-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non Hodgkin's lymphoma. Eur J Hematol 1997 59: 82-88.